Shorter radiation for prostate cancer recurrence? new trial tests 2-Week option
NCT ID NCT07500701
First seen Mar 31, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This phase 3 trial compares two types of radiation therapy for men whose prostate cancer has returned after surgery. One schedule takes 5-6 weeks, while the other is completed in just 2 weeks. The study aims to see if the shorter option works just as well with manageable side effects, potentially making treatment more convenient and less costly. It involves 270 participants across multiple centers in South Korea.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
RECRUITINGSeoul, Gangnam-gu, 06351, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radiotherapy (ultra-hypofractionated vs. moderate hypofractionated)
What this could lead to
If successful, this could offer a shorter, more convenient radiotherapy option for men with prostate cancer recurrence after surgery, reducing treatment time from weeks to just two weeks.
What could go wrong
This is an early-stage comparison in a specific group of patients, and the shorter schedule may not be as effective or could cause different side effects. Results may not apply to all prostate cancer patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.